Scott Alexander examines how compounding pharmacies are producing cheaper versions of GLP-1 agonist drugs, exploring the economics, safety, and future implications of this practice. Longer summary

Scott Alexander discusses the 'compounding loophole' that allows compounding pharmacies to produce cheaper versions of GLP-1 agonist drugs like semaglutide (Ozempic). He explains how these pharmacies operate, the cost differences, safety concerns, and potential future implications. The post covers the legal basis for this practice during drug shortages, the impact on drug manufacturers like Novo Nordisk, and speculates on what might happen when the shortage ends. Scott also touches on the broader implications for drug pricing and availability. Shorter summary

Scott Alexander analyzes the economic and societal implications of semaglutide, a new effective weight loss drug, and its potential to reshape obesity treatment. Longer summary

Scott Alexander explores the economic and societal impact of semaglutide, a new weight loss drug. He discusses its effectiveness, current limited availability, and potential future widespread use. The post covers the drug's history, its current pricing and accessibility issues, and projections for its future market. Scott also touches on the broader implications for obesity treatment and the possibility of a 'post-obesity' future. Shorter summary